This study investigates the prevalence of Small Intestinal Bacterial Overgrowth (SIBO) in patients with pancreatic adenocarcinoma.
The study evaluates the relationship between SIBO and weight loss in patients with pancreatic adenocarcinoma. It also looks at the prevalence of SIBO in patients who have had pancreatic surgery compared to those who have not.
- Who can participate: Individuals 18 years and older with pancreatic ductal adenocarcinoma and clinically diagnosed weight loss can participate. All genders are eligible, and consent is required.
- Study details: Participants will undergo a Lactulose Hydrogen Breath Test to check for SIBO. Some participants may receive a placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine.